Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Indolent non-Hodgkin lymphoma treatment in the new drugs era.

Literature DB >> 32075392

Indolent non-Hodgkin lymphoma treatment in the new drugs era.

Luis Miguel Juárez-Salcedo¹, Samir Dalia².

Abstract

Entities: Disease

Year: 2020 PMID： 32075392 DOI： 10.21037/cco.2020.01.01

Source DB: PubMed Journal: Chin Clin Oncol ISSN： 2304-3865

Keyword Cloud
Cited

× No keyword cloud information.

2 in total

1. The m⁶A methyltransferase WTAP plays a key role in the development of diffuse large B-cell lymphoma via regulating the m⁶A modification of catenin beta 1.

Authors: Shuangshuang Guo; Chunling Zhao; Liang Fang; Wenzhong Xu; Samir Dalia; Jon Glass; Naoto Shikama; Zhiye Zhang
Journal: Ann Transl Med Date: 2022-07

2. Pneumocystis jirovecii pneumonia in non-Hodgkin's lymphoma after rituximab-based chemotherapy: a case series.

Authors: Qianying Zhang; Liang Han; Yuanyuan Lin; Xiaohong Sun; Haige Ye; Honglan Qian; Lan Sun; Songfu Jiang; Bin Liang
Journal: Transl Cancer Res Date: 2022-07 Impact factor: 0.496

2 in total

Indolent non-Hodgkin lymphoma treatment in the new drugs era.

1. The m6A methyltransferase WTAP plays a key role in the development of diffuse large B-cell lymphoma via regulating the m6A modification of catenin beta 1.

2. Pneumocystis jirovecii pneumonia in non-Hodgkin's lymphoma after rituximab-based chemotherapy: a case series.

1. The m⁶A methyltransferase WTAP plays a key role in the development of diffuse large B-cell lymphoma via regulating the m⁶A modification of catenin beta 1.